Atem Capital: Deka Biosciences Closes USD $20M Series B2 Financing

Deka Biosciences, a Germantown, MD-based biotech company, raised USD $20M in Series B2 funding. The round was led by MPM BioImpact, with participation from Leaps by Bayer, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm. Additionally, Detlev Biniszkiewicz, Ph.D. of MPM-BioImpact, will join the Deka board. [...] The post Deka Biosciences Closes USD $20M Series B2 Financing appeared first on FinSMEs.